Darcy J. Mulford

Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-Medications (Including Proton Pump Inhibitors), and Pre-Existent Variability in Platelet Function

Andrew L. Frelinger, Deepak L. Bhatt, Ronald Lee et al. · Journal of the American College of Cardiology · 2013 · 203 citations

Thrombopoiesis, Thrombosis, Cardiovascular Disease +14

Pharmacokinetics and Pharmacodynamics of Febuxostat, a New Non-purine Selective Inhibitor of Xanthine Oxidase in Subjects with Renal Impairment

Michael D. Mayer, Reza Khosravan, Laurent Vernillet et al. · American Journal of Therapeutics · 2005 · 153 citations

A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers

Andrew L. Frelinger, Ronald Lee, Darcy J. Mulford et al. · Journal of the American College of Cardiology · 2012 · 147 citations

Pharmacological Study, Healthy Volunteers, Pharmacology +5

Febuxostat (TMX‐67), a Novel, Non‐Purine, Selective Inhibitor of Xanthine Oxidase, Is Safe and Decreases Serum Urate in Healthy Volunteers

Michael A. Becker, James C. Kisicki, Reza Khosravan et al. · Nucleosides Nucleotides & Nucleic Acids · 2004 · 96 citations

Molecular Pharmacology, Adverse Events, Urology +15

Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials

Majid Vakily, Weijiang Zhang, Jingtao Wu et al. · Current Medical Research and Opinion · 2009 · 92 citations